8-K: Sonnet BioTherapeutics Announces Positive Safety Results for SON-1010 in Combination with Atezolizumab, Advancing to Expansion Phase

Sonnet BioTherapeutics reports positive safety data for SON-1010 combined with atezolizumab in a Phase 1b/2a trial, allowing the study to proceed to the expansion phase.

Summary

• Sonnet BioTherapeutics announced positive safety results for SON-1010 in combination with atezolizumab in a Phase 1b/2a clinical trial.
• The trial, known as SB221, is studying adult patients with advanced solid tumors or platinum-resistant ovarian cancer (PROC).
• The Safety Review Committee (SRC) has given positive feedback, allowing the study to advance to the expansion phase.
• The expansion phase will assess the preliminary effect of the combination at the maximum tolerated dose (MTD) before a Phase 2a randomized comparison with the standard of care in PROC patients.
• The SB221 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of increasing doses of SON-1010 administered with atezolizumab.
• The primary goal of the first part of the study was to establish the MTD in combination with the immune checkpoint inhibitor (ICI).
• A total of 19 subjects were treated during dose escalation.
• One patient with PROC had a partial response at the highest dose.
• The SRC review concluded that fatigue, fevers, and gastrointestinal symptoms were the most common adverse effects, with no dose-limiting toxicity or cytokine release syndrome observed.
• The only related serious adverse event (SAE) during dose escalation was Grade 2 pneumonitis, a known adverse event with atezolizumab.
• One patient with PROC experienced a 44% tumor size reduction, indicating a partial response (PR), along with a more than 2-fold reduction in the CA 125 ovarian cancer biomarker.
• In the SB101 study, SON-1010 monotherapy led to a PR at the same MTD in a patient with sarcoma.
• The SB221 trial employed a desensitizing first dose of 300 ng/kg to minimize toxicity while allowing for higher maintenance doses.
• Of the 19 patients dosed, 8 of the 15 evaluable patients (53%) had stable disease (SD) at the first follow-up CT scan, and 5 of the 15 evaluable patients (33%) remained stable at four months.
• Four of those 15 patients were still on trial at 6 months, including 3 with SD and one with an unconfirmed PD.
• One of the PROC patients in the highest SON-1010 dose cohort had a PR at 2 months.

Sentiment

Score: 8

Explanation: The document presents positive safety results and the advancement of a clinical trial, suggesting a favorable outlook for the company's drug development program. The sentiment is high due to the potential for future clinical and commercial success.

Positives

• Positive safety results for SON-1010 in combination with atezolizumab.
• Advancement to the expansion phase of the SB221 study.
• Partial response observed in a PROC patient with a 44% tumor size reduction.
• Stable disease observed in 53% of evaluable patients at the first follow-up CT scan.
• Favorable safety and toxicity profile with mostly mild and transient adverse events.
• No evidence of cytokine release syndrome.

Negatives

• Fatigue, fevers, and gastrointestinal symptoms were the most common adverse effects.
• One related serious adverse event (SAE) of Grade 2 pneumonitis was reported, which is a known adverse event with atezolizumab.

Risks

• The study is still in early phases (Phase 1b/2a), and further trials are needed to confirm efficacy.
• The observed adverse effects, while mostly mild, could still impact patient tolerability and treatment adherence.
• The partial response was observed in only one patient, and the results may not be representative of the broader patient population.

Future Outlook

The study will now advance to the expansion phase to study the preliminary effect of the combination at the maximum tolerated dose (MTD), before proceeding to a Phase 2a randomized comparison with the standard of care in patients with PROC.

Industry Context

This announcement is relevant to the immuno-oncology space, where combination therapies involving immune checkpoint inhibitors like atezolizumab are being explored to improve outcomes in advanced solid tumors and ovarian cancer. The results contribute to the growing body of evidence on IL-12-based therapies in combination with checkpoint inhibitors.

Comparison to Industry Standards

• Atezolizumab (Tecentriq) is a well-established immune checkpoint inhibitor used in various cancer treatments, including ovarian cancer.
• The trial design, assessing safety and tolerability in Phase 1b/2a, is standard practice in oncology drug development.
• Partial response rates and stable disease rates are common metrics used to evaluate the efficacy of cancer therapies in early-stage trials.
• Companies like Roche (who manufacture Atezolizumab) and others developing similar combination therapies will be closely watching these results.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Patients with advanced solid tumors or PROC may have a new treatment option.
• Employees may experience increased job security and opportunities due to the company's progress.

Next Steps

• Advance to the expansion phase of the SB221 study.
• Study the preliminary effect of the combination at the maximum tolerated dose (MTD).
• Proceed to a Phase 2a randomized comparison with the standard of care in patients with PROC.

Key Dates

Keywords

SON-1010, atezolizumab, Sonnet BioTherapeutics, clinical trial, SB221, advanced solid tumors, platinum-resistant ovarian cancer, PROC, safety results, Phase 1b/2a, expansion phase, maximum tolerated dose, MTD, partial response, tumor reduction, CA 125, biomarker, stable disease